Zealand Pharma ZEAL.CO
DenmarkHealthcare · BiotechnologyNasdaq Copenhague · DKK
416.00 DKK (+66.8%)
12 analysts
XTB1.00 €affiliateOpen account ↗
Interactive Brokers4.74 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗Interactive Brokers4.74 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Zealand Pharma is a Danish biotech company focused on developing innovative peptide therapies for metabolic and gastrointestinal diseases, whose business model is based on the research, development, and subsequent commercialization or licensing of its drug candidates.
Listed on Nasdaq Copenhague · Symbol ZEAL.CO · CPH: ZEAL · Currency DKK
Key points
from its scores- ✓Very solid balance sheet9.4
- ✓Favourable backdrop8.2
- ✕Weak growth0.0
- ✕Poor share-price trend0.3
- ✕Little or no dividend1.5
AI analysis
bottom line, main risk, context and newsHold pending clinical or commercial catalysts that confirm a growth recovery; the strong cash position limits balance sheet risk, but the lack of momentum and positive results warrants caution.
Zealand Pharma shows solid financial health (score 9.42) with net cash (Net Debt/EBITDA of -6.04) and an operating margin of 85.93%, but its growth is currently negative (revenue -50.6%) and it does not generate free cash flow (FCF yield -12.47%), reflecting an intense R&D investment phase. The market valuation (P/E 6.45) discounts a future recovery that is not yet reflected in results.
The main risk is the regulatory and clinical development risk inherent to a biotech company: the failure of a drug candidate in late-stage trials or a delay in its approval could crush the growth expectations the market already prices in with a forward P/E of 33.28.
Context and risks
No relevant recent news. The macro context of interest rates and commodities does not materially affect a Danish biotech with net cash and no significant exposure to energy or shipping routes. The main risk is the inherent regulatory risk of drug development, already reflected in the market valuation.
Is Zealand Pharma stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 83% below the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 6.5 | 26.7 | −76% |
| EV / EBITDA | 1.4 | 14.5 | −90% |
| Price / book | 1.0 | 4.1 | −77% |
| Price / sales | 3.6 | 3.4 | +4% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 5.9 out of 10 (median for Healthcare: 4.7).
Average analyst target: 416.00 DKK, +66.8% versus the price.
A discount may reflect more risk or slower growth than its sector: Financial health 9.4 (sector 6.5), Growth 0.0 (sector 6.6).
Classic formulas with standard assumptions (0.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 6.5
- Forward P/E
- 33.3
- EV / EBITDA
- 1.4
- Price / book
- 1.0
- Price / sales
- 3.6
- Market cap
- 16.5B DKK
- Enterprise value
- 3.3B DKK
Profitability
- ROE
- 16.3%
- ROA
- 7.8%
- ROIC (approx.)
- 22.6%
- Gross margin
- 100.0%
- Operating margin
- 85.9%
- Net margin
- 59.0%
- Free cash flow
- −2.1B DKK
- FCF yield
- −12.5%
- Cash conversion
- −89%
Solvency
- Total debt
- 411.0M DKK
- Net debt
- −14.0B DKK
- Cash
- 14.5B DKK
- EBITDA
- 2.3B DKK
- Net debt / EBITDA
- −6.04
- Debt / equity
- 2.28
- Current ratio
- 13.98
- Quick ratio
- 13.76
Growth
- Revenue growth
- −50.6%
- Earnings growth
- −47.6%
- EPS (TTM)
- 38.64 DKK
- EPS (forward)
- 7.49 DKK
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- 0.61
- Analyst consensus
- Buy (12)
- Target price
- 416.00 DKK
- 52-week range
- 233.50 – 556.00
Recent news
All ZEAL.CO news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Zealand Pharma
Is Zealand Pharma stock cheap or expensive?
On P/E and EV / EBITDA, it trades 83% below the Healthcare median on average. Valuation score: 5.9 out of 10 (median for Healthcare: 4.7). Average analyst target: 416.00 DKK, +66.8% versus the price. This is not investment advice.
What score does Zealand Pharma get on MeridIAn Screener?
It scores 5.4 out of 10, rank 1,515 of 2,130 (better than 29% of the companies analysed). Its strongest category is Financial health (9.4) and its weakest, Growth (0.0). Analysis of 08/10/2026.
What is Zealand Pharma's P/E ratio?
Its P/E is 6.5: the share price equals 6.5 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 33.3.
How much is Zealand Pharma worth on the stock market?
Its market capitalisation is 16.5B DKK and its enterprise value, debt included, is 3.3B DKK.
How much debt does Zealand Pharma have?
It has more cash than debt: net cash of 14.0B DKK.
Does Zealand Pharma pay a dividend?
It pays no dividend, or almost none.
How has Zealand Pharma stock performed over the last year?
It has fallen 49.9% over the last year, excluding dividends. Over the last 52 weeks it has traded between 233.50 and 556.00 DKK. Past performance does not guarantee future results.
What do analysts think of Zealand Pharma?
12 analysts cover it; their average recommendation is “Buy” and their average target is 416.00 DKK (+66.8% versus the price). It is an estimate, not market data.